Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Magnet Makes NMR Less Costly

By Drug Discovery Trends Editor | April 25, 2013

[[{“fid”:”131236″,”view_mode”:”full”,”type”:”media”,”attributes”:{“height”:283,”width”:200,”style”:”float: left; margin: 3px;”,”class”:”media-element file-full”}}]]JEOL Resonance has developed a nuclear magnetic resonance (NMR) super conducting magnet that operates on a minimum amount of liquid helium.

JEOL’s NMR system is capable of acquiring high resolution NMR data when liquid helium is scarce. A super conducting magnet is typically cooled with liquid helium to keep its internal coil in the super conducting state and to maintain magnetic field intensity.

The JEOL Resonance zero boil off magnet will substantially reduce consumption of liquid helium by reliquifying the helium gas generated by evaporation of the helium in the magnet. In the event of a power outage the helium reservoir will maintain the magnetic field for 4 days. The cooling system design allows for biannual maintenance without affecting the high magnetic field of the super conducting magnet and minimizes vibration and noise that can interfere with NMR signals.

JEOL Resonance offers a line of magnets with a magnetic field intensity ranging from 400 MHz (9.4 T) to 930 MHz (21.8 T). The company plans to incorporate the new technology in the models of higher magnetic field intensities such as 500 MHz (11.7 T) and 600 MHz (14.1 T) to offer a complete line of NMR systems.

JEOL Resonance

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE